mariovitali
Senior Member
- Messages
- 1,214
I have reasons to believe that many ME/CFS patients will benefit from this therapy.
Welcome to Phoenix Rising!
Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of, and finding treatments for, complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia, long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.
To become a member, simply click the Register button at the top right.
The 500 dalton rule is the rule of thumb for transdermal absorption: if the molecular weight is above around 500 daltons, then it won't cross the skin.
and what about rectal absorption?
I have reasons to believe that many ME/CFS patients will benefit from this therapy.
@drewmaster
Since you are a new user, i am giving you a summary of the Research i've been doing : I use Machine Learning methods to identify the most relevant biological targets responsible for ME/CFS.
In the following post, the importance of Pyruvate Dehydrogenase was suggested almost one year before Fluge and Mella :
http://forums.phoenixrising.me/inde...e-treatment-for-cfs.37244/page-65#post-679562
However, please note also how the algorithm picks up Cortisol and Norepinephrine.
Here is another post that discusses HPA Axis :
http://forums.phoenixrising.me/inde...e-treatment-for-cfs.37244/page-91#post-814452
I believe that a big part of ME/CFS is HPA Axis dysregulation however the root problem is the Liver for most of us. I posted here several patient Fibroscans suggesting Liver Fibrosis. I met one Fibro patient 10 days ago who had Liver biopsy that showed Non-Alcoholic Steatohepatitis (NASH).
Again, it is suggested -according to my theory- that all ME/CFS Patients take a Fibroscan test to assess Liver status.
The Cortene Way: New Drug to Be Trialed in Chronic Fatigue Syndrome (ME/CFS) Soon – Pt. I
by Cort Johnson | Feb 8, 2018 | Homepage, Treatment | 10 comments
Research funding for chronic fatigue syndrome (ME/CFS) has been poor at best but clinical trials have elicited a wholly different degree of disappointment altogether. Few clinical trials are ever done and those are often involve alternative approaches. The 6 active clinical trials listed in clinicaltrials.gov, for instance, include treatments like acupuncture, moxibustion, oral rehydration and CoQ10.
That makes it shocking to see a “new” drug – a drug not being used in other diseases – get a clinical trial in ME/CFS. It wasn’t supposed to happen this way. First, it’s been assumed that repurposed drugs – drugs already in use in other disease – would be tested in ME/CFS to improve symptoms – and only later, as we understood the disease better, would we get to a drug that gets at the core problems in ME/CFS. This group is demolishing that timeline. They believe they have a drug that gets at the core of ME/CFS, and in the first quarter of this year they expect to test that drug.
Over the next month Health Rising will be publishing a 3 or 4-part blog series telling the story of the small group of researchers that are bringing a drug to ME/CFS they believe could get at the core of this disease.
The drug itself is highly experimental and the researchers behind it come from the biotechnology and drug development fields. They stumbled on ME/CFS by chance, but when they did the light bulbs went on. For the past year or two they’ve devoted their time to understanding ME/CFS and getting to the place where a clinical trial can take place.
Pereira was at a cocktail party discussing his drug with a well-known Stanford doctor, who was talking about some immune findings in a strange disease called ME/CFS. Pereira had not heard of the disease before, but the immune findings and ME/CFS in general seemed eerily reminiscent of the data he’d seen produced for CT38.
This is not to say that over time other medical issues haven’t shown up in some ME/CFS patients that could complicate their situation. That’s to be expected in any decades long disease. If Pereira and Cortene are right, though, the core of this disease might be amenable to a dramatic change.
Part 2 will examine Cortene’s hypothesis in greater detail and show how it explains the many symptoms and anomalies of ME/CFS. Part 3 will explain the treatment approach and provide details on the upcoming clinical trial. H(ealth Rising is not affiliated with Cortene in any manner.)
It looks like from this paper that astressin-B is a non-selective CRF1 and CRF2 antagonist, and astressin2-B is a selective CRF2 antagonist. Since we would want to target CRF2, astressin2-B would be best, but the astressin-B found in hair loss products might suffice.
Astressin-B is found in the Spectral.F7 hair loss product, whose ingredients are:
But as discussed above, since the molecular weight of astressin-B is 4042 daltons, and both the human skin and blood-brain barrier have a 500 dalton limit to the molecules that can cross them, getting astressin-B into the brain is a problem.
It is possible that intranasal administration of astressin-B might work, because the intranasal route apparently bypasses the blood-brain barrier; but there is still around a 2,000 dalton limit for molecules crossing the nasal mucous membranes, so it would be a long shot if any astressin-B got through.
.
I’ve spoken to one of the researchers, and I’d say that is not true. In my dealings, they have been very cautious about making claims and stressed several times that since there is no animal model to test, they have no idea how well it will work.Sounds like profit-oriented researchers have got a drug they don't fully understand and are willing to try it on me/cfs since we're eager to say the least.
It’s a biotech company.. they will get funded or not based on how solid the science is by biotech VCs, or a larger pharma, or private investors. Biotech is a business, like any other, only maybe more risky. I’m not sure why you would ascribe these kinds of negative qualities to them.Sounds like profit-oriented researchers have got a drug they don't fully understand and are willing to try it on me/cfs since we're eager to say the least.
Ema, is the trial funded?I’ve spoken to one of the researchers, and I’d say that is not true.